1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C312D421279F3343852584B10028E811
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-raising-phase-four-performance-value-through-optimal-msl-involvement-roles-impact-training-development?opendocument
18
19opendocument
203.95.131.208
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

Raising Phase IV Performance & Value Through Optimal MSL Involvement: MSL Roles, Impact & Training & Development

ID: 5586


Features:

14 Info Graphics

16 Data Graphics

160+ Metrics

6 Narratives


Pages/Slides: 37


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Raising Phase IV Performance & Value Through Optimal MSL Involvement: MSL Roles, Impact & Training & Development”

STUDY OVERVIEW


As payers and regulatory bodies increasingly demand real world evidence for key decision making, it is important to reflect key stakeholder perspectives in Phase IV study design and execution. And MSLs are well positioned to be a conduit of HCP, thought leader, and payer insights about the evidence generation targets that matter most.

However, optimizing MSL contributions requires that organizations allocate the right field medical personnel at the right times in the Phase IV development and execution process.

Best Practices, LLC undertook this benchmarking research to probe how leading pharmaceutical and biotech organizations are raising Phase IV performance and value through optimal involvement of MSLs. This study characterizes the MSL contributions most essential to Phase IV, spotlights Phase IV opportunity fronts for MSL deployment, along with the field team skills and training that help maximize MSL impact on Phase IV studies.

KEY TOPICS

  • Key MSL Roles in Phase IV Studies
  • Measuring the Impact of MSL Involvement
  • MSL Skills and Competencies for Phase IV
  • MSL-Phase IV Training

KEY METRICS
  • What Phase IV study activities are MSLs involved with at your company?
  • Do MSLs lead, support, or inform the stakeholder mapping for Phase IV studies?
  • Rate the importance of MSL involvement in stakeholder mapping, from critically important to not important
  • From poor to excellent, what is the current Phase IV capability for the MSLs at your company?
  • What skills are most important for MSLs in regards to Phase IV study involvement?
  • Does your organization train MSLs on skills needed to support Phase IV studies specifically, or are these skills trained for within other training regimens?
  • Among all Phase IV study skills, which are the most essential when making the hiring decision?

SAMPLE KEY FINDINGS
  • MSL-Phase IV Activity Opportunity Front – Informing Study Design: Some organizations have started using the collective power of study-relevant MSLs to vet study design & outcome measures for relevance to real world clinical practice.
  • Top Performing Organizations Target RWE & Study Design for Expanded Training in the Next Year: RWE trainings will drive MSL contribution to evidence gap mapping, while the objective of study design training is to increase general knowledge.

METHODOLOGY

Best Practices, LLC engaged 43 Medical Affairs leaders from 31 pharmaceutical and biotechnology companies in this research through a benchmarking survey and interviews.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Health Care


Companies Profiled:
AbbVie; Alkermes; BeiGene; BioDelivery Sciences International; Inc.; Biogen; BioMarin; BTG plc; Cipla; Eisai; EMD Serono; Impel NeuroPharma; Intas; Ipsen; Janssen; La Jolla Pharmaceutical; Mayne; Melinta Therapeutics; Inc; Merck; Merck KGaA; Milestone Pharmaceuticals; Myriad Genetics; Novartis; Pfizer; Rakuten Medical; Searle; Shire; Sunovion; Taiho Pharma; Takeda Pharmaceuticals; UniQure; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.